Raddur Samaddar, Team bioXone
The pandemic is going about its length and breadth, in India, we have 9,43,990 active cases as of 2nd October 2020. The serological activity and also the cross-reactivity of the diseases are a major concern at this moment. A commercial SARS-CoV-2 ELISA test was used for patients diagnosed as Dengue, Zika, and Chikungunya infected between 2015 and 2019, from an endemic area at the Caribbean Colombian region. The results were pretty much suggestive of the cross-reactivity between the two infections. A total of 127 sera were collected in 6 groups and were analysed for the results. The patients were grouped into 3 divisions for the study – according to Faccini-Martinez et al (2020).
Group A: patients with confirmed SARS-CoV-2 infection.
Group B: patients having suggestive symptoms of COVID-19 also asymptomatic contacts of confirmed COVID-19 patients.
Group C: patients with acute or recent dengue virus infection.
Group D: patients with acute Zika virus infection.
Group E: patients with previous Chikungunya virus infection.
Group F: individuals with exposure to spotted fever group rickettsiae.
The results of cross-reactivity obtained were astonishing. Overall Group A, B and D showed extents of serological cross-reactivity while others were entirely seronegative. Studied results can be accessed at the Elsevier Published Research Article. Some conclusions drawn by Faccini-Martinez et al (2020) suggests that serological cross-reactivities can be studied to analyse the time frame based derivations in accordance to acute and non-acute patients, with previous exposure to the Zika virus and its effect in SARS-CoV-2 serological surveys in endemic areas for this arbovirus.
Reference: Faccini-Martínez ÁA, Rivero R, Garay E, García A, Mattar S, Botero Y, Galeano K, Miranda J, Martínez C, Guzmán C, Arrieta G, Contreras H, Kerguelen H, Moscote M, Brango E, Contreras V. Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia. Int J Infect Dis. 2020 Sep 28:S1201-9712(20)32167-6. doi: http://10.1016/j.ijid.2020.09.1451. Epub ahead of print. PMID: 33002616.
Also read: Area 32 establishes parity between your cognitive abilities and emotional expression
Life Science Clinical Data Manager Job Vacancy at Novartis
-Shristi Sharma, Team bioXone MSc Life Science candidates apply online for a Clinical Data Manager position that is available at Novartis. Novartis is hiring MSC candidates, as per the details below in their Research & Development area: Job Title: Clinical Data Manager Job ID: 303627BR Division: Global Drug Development Business Unit: GDO GDD Employment Type: […]